Cargando…
Molnupiravir and Its Antiviral Activity Against COVID-19
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden. The pandemic is still ongoing and the SARS-CoV-2 variants are still emerging constantly, resulting in an urg...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013824/ https://www.ncbi.nlm.nih.gov/pubmed/35444647 http://dx.doi.org/10.3389/fimmu.2022.855496 |
_version_ | 1784688079871672320 |
---|---|
author | Tian, Lili Pang, Zehan Li, Maochen Lou, Fuxing An, Xiaoping Zhu, Shaozhou Song, Lihua Tong, Yigang Fan, Huahao Fan, Junfen |
author_facet | Tian, Lili Pang, Zehan Li, Maochen Lou, Fuxing An, Xiaoping Zhu, Shaozhou Song, Lihua Tong, Yigang Fan, Huahao Fan, Junfen |
author_sort | Tian, Lili |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden. The pandemic is still ongoing and the SARS-CoV-2 variants are still emerging constantly, resulting in an urgent demand for new drugs to treat this disease. Molnupiravir, a biological prodrug of NHC (β-D-N(4)-hydroxycytidine), is a novel nucleoside analogue with a broad-spectrum antiviral activity against SARS-CoV, SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), influenza virus, respiratory syncytial virus (RSV), bovine viral diarrhea virus (BVDV), hepatitis C virus (HCV) and Ebola virus (EBOV). Molnupiravir showed potent therapeutic and prophylactic activity against multiple coronaviruses including SARS-CoV-2, SARS-CoV, and MERS-CoV in animal models. In clinical trials, molnupiravir showed beneficial effects for mild to moderate COVID-19 patients with a favorable safety profile. The oral bioavailability and potent antiviral activity of molnupiravir highlight its potential utility as a therapeutic candidate against COVID-19. This review presents the research progress of molnupiravir starting with its discovery and synthesis, broad-spectrum antiviral effects, and antiviral mechanism. In addition, the preclinical studies, antiviral resistance, clinical trials, safety, and drug tolerability of molnupiravir are also summarized and discussed, aiming to expand our knowledge on molnupiravir and better deal with the COVID-19 epidemic. |
format | Online Article Text |
id | pubmed-9013824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90138242022-04-19 Molnupiravir and Its Antiviral Activity Against COVID-19 Tian, Lili Pang, Zehan Li, Maochen Lou, Fuxing An, Xiaoping Zhu, Shaozhou Song, Lihua Tong, Yigang Fan, Huahao Fan, Junfen Front Immunol Immunology The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden. The pandemic is still ongoing and the SARS-CoV-2 variants are still emerging constantly, resulting in an urgent demand for new drugs to treat this disease. Molnupiravir, a biological prodrug of NHC (β-D-N(4)-hydroxycytidine), is a novel nucleoside analogue with a broad-spectrum antiviral activity against SARS-CoV, SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), influenza virus, respiratory syncytial virus (RSV), bovine viral diarrhea virus (BVDV), hepatitis C virus (HCV) and Ebola virus (EBOV). Molnupiravir showed potent therapeutic and prophylactic activity against multiple coronaviruses including SARS-CoV-2, SARS-CoV, and MERS-CoV in animal models. In clinical trials, molnupiravir showed beneficial effects for mild to moderate COVID-19 patients with a favorable safety profile. The oral bioavailability and potent antiviral activity of molnupiravir highlight its potential utility as a therapeutic candidate against COVID-19. This review presents the research progress of molnupiravir starting with its discovery and synthesis, broad-spectrum antiviral effects, and antiviral mechanism. In addition, the preclinical studies, antiviral resistance, clinical trials, safety, and drug tolerability of molnupiravir are also summarized and discussed, aiming to expand our knowledge on molnupiravir and better deal with the COVID-19 epidemic. Frontiers Media S.A. 2022-04-04 /pmc/articles/PMC9013824/ /pubmed/35444647 http://dx.doi.org/10.3389/fimmu.2022.855496 Text en Copyright © 2022 Tian, Pang, Li, Lou, An, Zhu, Song, Tong, Fan and Fan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tian, Lili Pang, Zehan Li, Maochen Lou, Fuxing An, Xiaoping Zhu, Shaozhou Song, Lihua Tong, Yigang Fan, Huahao Fan, Junfen Molnupiravir and Its Antiviral Activity Against COVID-19 |
title | Molnupiravir and Its Antiviral Activity Against COVID-19 |
title_full | Molnupiravir and Its Antiviral Activity Against COVID-19 |
title_fullStr | Molnupiravir and Its Antiviral Activity Against COVID-19 |
title_full_unstemmed | Molnupiravir and Its Antiviral Activity Against COVID-19 |
title_short | Molnupiravir and Its Antiviral Activity Against COVID-19 |
title_sort | molnupiravir and its antiviral activity against covid-19 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013824/ https://www.ncbi.nlm.nih.gov/pubmed/35444647 http://dx.doi.org/10.3389/fimmu.2022.855496 |
work_keys_str_mv | AT tianlili molnupiraviranditsantiviralactivityagainstcovid19 AT pangzehan molnupiraviranditsantiviralactivityagainstcovid19 AT limaochen molnupiraviranditsantiviralactivityagainstcovid19 AT loufuxing molnupiraviranditsantiviralactivityagainstcovid19 AT anxiaoping molnupiraviranditsantiviralactivityagainstcovid19 AT zhushaozhou molnupiraviranditsantiviralactivityagainstcovid19 AT songlihua molnupiraviranditsantiviralactivityagainstcovid19 AT tongyigang molnupiraviranditsantiviralactivityagainstcovid19 AT fanhuahao molnupiraviranditsantiviralactivityagainstcovid19 AT fanjunfen molnupiraviranditsantiviralactivityagainstcovid19 |